Liver Cirrhosis, Transjugular Intrahepatic Portosystemic Shunt (TIPS), Heart Failure
Conditions
Brief summary
The purpose of this study is to conduct a prospective trial to investigate the incidence of heart failure in cirrhosis patients undergoing transjugular intrahepatic portosystemic shunt ,and to analyze the the predictors and modififications of cardiac function.
Detailed description
Hyperdynamic circulation is a common Phenomenon in cirrhosis due to systemic and splanchnic vasodilatation, which may result cardic dysfunction and abnormal structure ,called cirrhotic cardiomyopathy(CCM). Transjugular intrahepatic portosystemic shunt (TIPS), as a effective technique to alleviates portal hypertension in cirrhotic patients, often be used to treat with refractory ascites and variceal bleeding which endoscopy and drug therapy are ineffective. However, owing to the increased shunting of blood from the splanchnic vascular bed into the central vascular bed, TIPS further exacerbates the hyperdynamic circulatory state, which may lead to heart failure.yet there are no convincing research to study the incidence of heart failure in cirrhosis after transjugular intrahepatic portosystemic shunt. The purpose of this study is to conduct a prospective trial to investigate the incidence of heart failure in cirrhotic patients undergoing transjugular intrahepatic portosystemic shunt ,and to analyze the the predictors and modififications of cardiac function.
Interventions
PROCEDURETIPS
TIPS: Established distributary channel between the portal vein and hepatic vein via the jugular vein, portal vein blood directly shunts into the systemic circulation to reduce portal vein pressure to effectively prevent bleeding and refractory ascites.
Sponsors
West China Hospital
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Cirrhosis 2. TIPS is placed successfully 3. Agree to participate in the trial
Exclusion criteria
1. Non-cirrhotic portal hypertension 2. Previous TIPS or surgical shunt 3. Medium to severe pulmonary hypertension 4. Heart failure 5. End-stage renal disease requiring hemodialysis 6. Respiratory failure 7. Malignancies with a life expectancy of less than 6 months
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of heart failue | up to 36 months | Heart failue assessed by2021 ESC Guidelines |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| mortality | up to 36 months | Telephone follow-up was performed to collect relevant information |
| Modififications of cardiac function | up to 36 months | Echocardiography was to evaluate cardic function |
| Predictors of heart Failure | up to 36 months | Heart failue assessed by2021 ESC Guidelines |
Countries
China
Contacts
Primary ContactXuefeng Luo
Outcome results
None listed